Latest News on HALO

Financial News Based On Company


Advertisement
Advertisement

Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh Pressure

https://www.benzinga.com/trading-ideas/movers/26/11/63448265/halozyme-stock-slides-european-patent-fight-with-merck-spurs-fresh-pressure
Halozyme Therapeutics shares are trading lower after a German court overturned a preliminary injunction that had temporarily halted Merck's Keytruda SC launch in Germany. Halozyme plans to immediately file an infringement lawsuit seeking permanent relief and noted a separate Dutch court decision prohibiting Keytruda SC manufacturing and sales in several European countries. Despite the setback, the stock maintains strong momentum and quality scores, though its valuation is seen as weak.

Halozyme Loses German Keytruda SC Block and Plans New Lawsuit

https://www.securities.io/halozyme-loses-german-keytruda-sc-block-and-plans-new-lawsuit/
Halozyme Therapeutics lost a preliminary injunction in Germany that had blocked Merck's distribution of Keytruda SC, but plans to file a new infringement lawsuit seeking permanent relief. This German legal battle is separate from a Dutch court order that found Merck infringed Halozyme’s MDASE patent and restricts Keytruda SC activities in eight European markets. Halozyme emphasizes that its MDASE patent enforcement campaign is distinct from its ENHANZE licensing program and will not impact its revenue from those agreements.

MSD Wins All 14 U.S. Patent Trials Against Halozyme, Easing Patent Risk for Subcutaneous Keytruda

https://finance.biggo.com/news/5cbc8f34-39d5-40b8-9025-821acf3c2f3d
MSD has won all 14 U.S. patent invalidation challenges against Halozyme Therapeutics regarding its MDASE technology, which converts drugs to subcutaneous formulations. This decision significantly eases patent risk for Keytruda Qlex, MSD's subcutaneous cancer drug utilizing Alteogen's ALT-B4 technology, which recently received FDA approval and generated $830 million in Q3 sales. However, the dispute is not fully resolved as Halozyme may appeal the PTAB decision, and a related patent infringement lawsuit in federal court remains pending.

Form 4 Halozyme Therapeutics Inc: Matthew L. Posard (Director) For: 18 November

https://ca.investing.com/news/stock-market-news/form-4-halozyme-therapeutics-inc-matthew-l-posard-director-for-18-november-93CH-4968238
This article reports on a Form 4 filing for Halozyme Therapeutics Inc, specifically detailing an insider transaction involving director Matthew L. Posard. The transaction occurred on November 18, 2026. The article primarily serves as a brief announcement of the filing without providing further details on the nature of the transaction.

Halozyme Therapeutics director Matthew Posard sells $482,146 in stock

https://www.investing.com/news/insider-trading-news/halozyme-therapeutics-director-matthew-posard-sells-482146-in-stock-93CH-5037392
Matthew L. Posard, a director at Halozyme Therapeutics, Inc. (NASDAQ:HALO), sold 5,000 shares of common stock for a total of $482,146 on November 18, 2026. The sales were conducted through a pre-arranged trading plan, and Posard still beneficially owns 48,609 shares. This transaction follows strong third-quarter 2026 earnings for Halozyme, which exceeded analyst expectations, though the stock has seen a recent pullback.
Advertisement

Under a preset trading plan, a Halozyme (HALO) director sold 5,000 shares in two trades.

https://www.stocktitan.net/sec-filings/HALO/form-4-halozyme-therapeutics-inc-insider-trading-activity-1f024b63b1c0.html
Halozyme Therapeutics, Inc. director Matthew L. Posard sold a total of 5,000 common shares on November 18, 2026, across two transactions. These sales were executed under a Rule 10b5-1 trading plan established on June 15, 2026, with shares sold at weighted-average prices of $96.1730 and $96.9740. After these transactions, Posard directly holds 48,609 shares of common stock.

HALO Rallies More Than 40% in 6 Months: How Should You Play the Stock?

https://www.tradingview.com/news/zacks:02100666f094b:0-halo-rallies-more-than-40-in-6-months-how-should-you-play-the-stock/
Halozyme Therapeutics (HALO) has seen its stock rally over 40% in the past six months, driven by strong performance of its ENHANZE drug delivery technology and strategic acquisitions. The company's revenue guidance for 2026 has been raised, reflecting increased royalty payments from partners and growing product sales. While HALO trades at a premium, analysts maintain a "Hold" rating due to continued growth prospects and diversified technology offerings, tempered by reliance on partner revenues.

Form 4 Halozyme Therapeutics Inc: Helen Torley (Director, PRESIDENT AND CEO) For: 12 November

https://ca.investing.com/news/stock-market-news/form-4-halozyme-therapeutics-inc-helen-torley-director-president-and-ceo-for-12-november-93CH-4962587
This article reports on a Form 4 filing for Halozyme Therapeutics Inc, detailing an insider transaction by Helen Torley, who holds positions as Director, President, and CEO. The filing pertains to activity on November 12.

Form 144 HALOZYME THERAPEUTICS INC For: 15 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-halozyme-therapeutics-inc-for-15-november-93CH-4959075
This article from Investing.com announces the filing of Form 144 for HALOZYME THERAPEUTICS INC on November 15, 2026. Form 144 indicates an intent to sell restricted or control securities by an insider. The brief article provides a direct report without further details on the transaction.

Why Is Halozyme Therapeutics (HALO) Drawing Fresh Attention Today?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/why-is-halozyme-therapeutics-halo-drawing-fresh-attention-to
Halozyme Therapeutics recently reported strong third-quarter 2026 results and raised its full-year guidance, leading to fresh investor interest. Despite this positive news, the share price experienced a short-term pullback, although its year-to-date and one-year returns remain strong. The market is currently weighing the upbeat report against valuation concerns raised by brokers, with some community investors suggesting the stock is significantly undervalued based on its multi-platform strategy.
Advertisement

Can You Make Money Off Halozyme Stock Now?

https://www.trefis.com/stock/halo/articles/624246/can-you-make-money-off-halozyme-stock-now/2026-11-11
Halozyme Therapeutics stock has dropped 21.5% recently, prompting investors to consider buying opportunities. Historically, a majority of similar past dips have led to gains for buyers a year later, though often after further initial declines. The company's royalty revenues are growing, and a patent dispute with Merck in Europe has favored Halozyme, though U.S. patent validity is still under appeal.

Halozyme downgraded at Morgan Stanley on valuation

https://www.tradingview.com/news/seekingalpha:5b63d16c5094b:0-halozyme-downgraded-at-morgan-stanley-on-valuation/
Halozyme Therapeutics (HALO) shares fell after Morgan Stanley downgraded the stock to Equal Weight from Overweight due to valuation concerns following its Q3 2026 results. Analyst Sean Laaman raised the price target to $109 from $105, noting the stock now trades in line with his base case after a recent selloff and significant year-to-date gains. The downgrade also considers future royalty-rate step-downs for its largest revenue stream, Darzalex SC.

Morgan Stanley Downgrades Halozyme As Royalties Face A 2029 Peak

https://finimize.com/content/morgan-stanley-downgrades-halozyme-as-royalties-face-a-2029-peak
Morgan Stanley downgraded Halozyme Therapeutics to "equal weight" despite raising its price target to $109, anticipating that the company's Enhanze royalty growth will likely peak in 2029 due to contractual step-downs. The bank sees the company's future growth relying on new programs like Hypercon and antibody-drug conjugates, though these early-stage projects carry significant risk. While near-term business looks healthy with raised 2026 revenue guidance, the stock's valuation is increasingly dependent on less certain pipeline value.

Halozyme Therapeutics downgraded by Morgan Stanley with a new price target

https://www.quantisnow.com/insight/halozyme-therapeutics-downgraded-by-morgan-stanley-with-a-new-price-6785165
Morgan Stanley has downgraded Halozyme Therapeutics (HALO) from Overweight to Equal-Weight, setting a new price target of $109.00. This analyst rating change was delivered to Quantisnow Plus members in real-time, providing an immediate alert on the stock. Historical data shows varied stock performance following previous headlines for HALO, with a median move of 2.2% in either direction.

MSD Wins 12 of 14 Patent Invalidity Trials Against Halozyme SC Patents; Alteogen Seen Gaining Relief From U.S. Patent Burden

https://finance.biggo.com/news/361fad61-5583-4f1c-a5bf-21b7f8de2bda
The U.S. Patent Trial and Appeal Board (PTAB) ruled that all 30 challenged claims of Halozyme Therapeutics' subcutaneous injection formulation patent 12,037,618 are unpatentable, marking MSD's 12th victory in 14 post-grant reviews against Halozyme's MDASE patents. This decision is expected to ease the U.S. patent burden for Alteogen, whose ALT-B4 technology is used in MSD's Keytruda SC. However, Halozyme may appeal the decision, and a conflicting trend is seen in Europe where a Dutch court has banned Keytruda SC sales in eight countries.
Advertisement

Weekly Recap: Q3 earnings growth and RYBREVANT FASPRO FDA approval

https://www.tradingview.com/news/tradingview:e024125b02aab:0-weekly-recap-q3-earnings-growth-and-rybrevant-faspro-fda-approval/
Halozyme Therapeutics (NASDAQ:HALO) reported a strong Q3 2026 with a 39% revenue increase to $493 million and non-GAAP EPS of $2.39, exceeding estimates. The company also announced FDA accelerated approval for Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme's ENHANZE technology. Additionally, Halozyme anticipates minimal impact from new Medicare drug-price rules and saw significant conversion to OCREVUS Zunovo.

Halozyme Stock Down Despite Q3 Earnings and Revenue Beat

https://www.tradingview.com/news/zacks:068d9f144094b:0-halozyme-stock-down-despite-q3-earnings-and-revenue-beat/
Halozyme Therapeutics reported strong Q3 2026 earnings and revenue, beating Zacks Consensus Estimates with a 39% increase in earnings and 39.2% increase in total revenues year-over-year. Despite these positive results, the company's stock fell over 6% in after-hours trading. Halozyme also raised its full-year 2026 guidance for total revenues and earnings, though investors were seemingly unimpressed with the sales outlook.

Halozyme stock dips as Leerink downgrades on Q3 (HALO:NASDAQ)

https://seekingalpha.com/news/4668330-halozyme-stock-dips-leerink-downgrades-q3
Halozyme Therapeutics stock fell over 13% after Leerink Partners downgraded the company. The downgrade followed Halozyme's Q3 2026 results, which analysts noted only marginally exceeded Street forecasts, prompting concerns about the company's performance.

Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029

https://www.prnewswire.com/news-releases/halozyme-reaffirms-it-projects-zero-to-minimal-impact-to-royalty-revenue-through-at-least-2035-based-on-medicare-drug-price-negotiation-program-final-rule-for-ipay-2029-302932131.html
Halozyme Therapeutics, Inc. announced that it expects zero to minimal impact on its royalty revenue through at least 2035, based on its analysis of the final rule for the Medicare Drug Price Negotiation Program. The company's CEO, Dr. Helen Torley, stated that this outlook is supported by the final rule affirming orphan drug protections and addressing the impacts of biosimilar entry. Halozyme also projects no impact on its ability to execute new ENHANZE® partnership agreements.

Halozyme Therapeutics, Inc. (HALO) Projects Zero To Minimal Royalty Impact Through 2035

https://www.tradingview.com/news/tradingview:a83b291c702f4:0-halozyme-therapeutics-inc-halo-projects-zero-to-minimal-royalty-impact-through-2035/
Halozyme Therapeutics, Inc. (HALO) projects that the CMS's final Medicare drug price negotiation rule will have zero to minimal impact on its royalty revenue through at least 2035. The company also anticipates no effect on its ability to forge new ENHANZE partnerships. This outlook is based on an analysis of the final rule issued on November 5, 2026.
Advertisement

Halozyme Q3 2026: Record Royalties Drive a Guidance Raise

https://247wallst.com/cards/halozyme-therapeutics-q3-2026-earnings-halo-01m6prps2mjnj2wsmdj9kwnv8s
Halozyme Therapeutics reported strong Q3 2026 results, with non-GAAP EPS of $2.39 and revenue up 39.1% year over year, driven by record ENHANZE royalty income of $341 million. This led management to raise its full-year 2026 guidance for revenue, royalty revenue, and non-GAAP diluted EPS, highlighting the company's shift towards high-margin royalty streams. Despite the positive report, shares experienced a slight dip immediately after the release.

[Halozyme Therapeutics Q3 2026 Earnings Call] Halozyme Raises Guidance as Revenue Jumps 39% to $493M and Dutch Court Blocks Merck's Keytruda QLEX in Eight European Markets

https://finance.biggo.com/news/US_HALO_2026-11-05
Halozyme Therapeutics reported a strong third quarter in 2026, with total revenue jumping 39% to $493 million and royalty revenue rising 44% to $341 million. The company raised its full-year 2026 guidance and secured a significant legal victory in Europe, where a Dutch court ruled that Merck's KEYTRUDA QLEX infringes on Halozyme's EP622 patent, blocking its launch in eight European countries. Despite facing U.S. litigation challenges, Halozyme remains confident in its ENHANZE platform, pipeline expansion, and advancing hyperconcentration technologies for sustained growth.

Halozyme falls 6% as raised guidance fails to impress investors By Investing.com

https://www.investing.com/news/earnings/halozyme-falls-6-as-raised-guidance-fails-to-impress-investors-5006041
Halozyme Therapeutics Inc. shares dropped 6% in after-hours trading despite reporting strong third-quarter results that surpassed Wall Street expectations. The biotechnology company raised its full-year 2026 guidance for revenue, adjusted EPS, and adjusted EBITDA, but the updated outlook still fell short of elevated investor expectations. Royalty revenue, a key driver, saw a 44% year-over-year increase, and the company achieved a legal victory regarding patent infringement.

Halozyme Therapeutics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62958934/halozyme-therapeutics-q3-2026-earnings-call-transcript
Halozyme Therapeutics reported strong Q3 2026 financial results with a 39% increase in total revenue to $493 million and a 44% rise in royalty revenue to $341 million, driven by the continued growth of ENHANZE-enabled products like Darzalex Subcutaneous and Vyvgart Hytrulo. The company expanded its ENHANZE opportunity with new target nominations and advanced multiple programs into clinical development, raising its full-year 2026 revenue guidance. Halozyme also secured significant legal victories in Europe against Merck regarding its Keytruda subcutaneous patent, preventing its launch in key markets, and is progressing its HyperCon and AeroCon hyperconcentration technologies towards clinical trials in 2027 and 2028, respectively.

Halozyme Therapeutics (NASDAQ:HALO) surprises with Q3 2026 sales but stock drops

https://uk.finance.yahoo.com/news/halozyme-therapeutics-nasdaq-halo-surprises-211024585.html
Halozyme Therapeutics (NASDAQ:HALO) reported better-than-expected Q3 2026 revenue of $493 million, up 39.2% year-on-year, and raised its full-year revenue and EBITDA guidance. Despite these positive financial results and strong long-term revenue growth, the company's stock dropped by 5.6% immediately after the announcement. The decline was attributed to the market potentially hoping for even stronger results, despite the solid performance.
Advertisement

HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

https://www.prnewswire.com/news-releases/halozyme-reports-third-quarter-2026-results-and-raises-full-year-2026-financial-guidance-302931338.html
Halozyme Therapeutics, Inc. reported strong third-quarter 2026 financial results, with total revenue up 39% and royalty revenue up 44% year-over-year. The company raised its full-year 2026 financial guidance, anticipating significant growth in total revenue, royalty revenue, Adjusted EBITDA, and Non-GAAP diluted EPS. Halozyme also highlighted key milestones including expanded ENHANZE collaboration agreements and a patent infringement victory against Merck.

Halozyme falls 6% as raised guidance fails to impress investors

https://finance.yahoo.com/healthcare/articles/halozyme-falls-6-raised-guidance-232957265.html
Halozyme Therapeutics Inc. (NASDAQ:HALO) reported better-than-expected third-quarter results, with adjusted EPS of $2.39 and revenue climbing 39% YoY to $493 million. However, shares fell 6% in after-hours trading as the company's raised full-year 2026 guidance, while slightly above consensus, failed to meet elevated investor expectations. The company also announced expanded ENHANZE collaboration agreements, progress in clinical development, and a legal victory against Merck.

Halozyme Therapeutics (NASDAQ:HALO) surprises with Q3 2026 sales but stock drops

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-5-halozyme-therapeutics-nasdaqhalo-surprises-with-q3-2026-sales-but-stock-drops
Halozyme Therapeutics reported better-than-expected Q3 2026 revenue of $493 million, a 39.2% year-on-year increase, and raised its full-year revenue and adjusted EPS guidance. Despite strong financial performance and expanded agreements, the company's stock dropped 5.6% immediately after the results were announced. The article details the company's financial highlights, revenue and EPS growth, and adjusted operating margins.

Halozyme Therapeutics (HALO) Could Be 14% Undervalued As Earnings Estimates Rise

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/halozyme-therapeutics-halo-could-be-14-undervalued-as-earnin
Halozyme Therapeutics (HALO) is heading into its Q3 2026 earnings release with strong recent share price performance, up 20.34% in one month and 90.83% in one year. The company is considered 14% undervalued with a fair value of $151.83 against a current close of $130.34, although its P/E ratio of 35.8x suggests valuation risk. Halozyme is expanding beyond its ENHANZE® platform to create a portfolio of drug-delivery technologies.

What Investors Overlooked Before Halozyme Therapeutics' 88% Run

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/what-investors-overlooked-before-halozyme-therapeutics-88-ru
Halozyme Therapeutics experienced an 88.3% return over the past year, prompting a look back at the differing analyst expectations in late 2025. Investors faced a choice between a bullish outlook, predicting growth from expanding subcutaneous partnerships, and a bearish view, concerned about ENHANZE dependence and potential patent expiry. Recent financial results showed significant revenue growth, but a slight dip in net margin, indicating that while the company is expanding its royalty stream, profitability per deal remains a key area to monitor.
Advertisement

Halozyme Therapeutics (HALO) Q3 earnings report preview: what to look for

https://stockstory.org/us/stocks/nasdaq/halo/news/earnings/halozyme-therapeutics-halo-q3-earnings-report-preview-what-to-look-for
Halozyme Therapeutics (NASDAQ:HALO) is set to announce its Q3 earnings this Thursday after market hours. The company has a history of exceeding Wall Street's expectations and analysts have reconfirmed their estimates for this quarter, anticipating 37.3% year-on-year revenue growth. Investor sentiment in the therapeutics segment is positive, with Halozyme Therapeutics's shares up 18% over the last month.

Halozyme Therapeutics (HALO) Q3 earnings report preview: what to look for

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-4-halozyme-therapeutics-halo-q3-earnings-report-preview-what-to-look-for
Halozyme Therapeutics (NASDAQ: HALO) is set to announce its Q3 earnings, with analysts expecting a 37.3% year-on-year revenue increase. The company has a history of exceeding expectations, and its stock has performed well, up 18% over the last month, outperforming the therapeutics segment average. Investors will be watching closely after strong Q3 results from peers like Biogen and Amgen.

JP Morgan maintains Halozyme Therapeutics at Neutral, raises price target to $79 from $78

https://www.tradingview.com/news/tradingview:2520619496e01:0-jp-morgan-maintains-halozyme-therapeutics-at-neutral-raises-price-target-to-79-from-78/
JP Morgan has maintained its "Neutral" rating for Halozyme Therapeutics, while increasing its price target to $79 from $78. This new price target implies a significant downside of 38.7% from the stock's closing price on November 2nd. Other recent analyst actions on Halozyme Therapeutics include "Buy" ratings from TD Cowen and HC Wainwright & Co. with price targets of $130.

(HALO) as a Liquidity Pulse for Institutional Tactics

https://news.stocktradersdaily.com/news_release/43/HALO_as_a_Liquidity_Pulse_for_Institutional_Tactics_110126042202_1793568122.html
An analysis of Halozyme Therapeutics Inc. (NASDAQ: HALO) indicates strong sentiment across all horizons, supporting an overweight bias. The article provides three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. Multi-timeframe signal analysis also highlights strong support and resistance levels for near-term, mid-term, and long-term horizons.

Halozyme Therapeutics, Inc. (HALO) Seasonal returns chart

https://uk.finance.yahoo.com/quote/HALO/seasonality/
This article provides a seasonal returns chart for Halozyme Therapeutics, Inc. (HALO), showing the average monthly price return from 2016 to 2026. It includes current stock performance details and related financial data.
Advertisement

Halozyme Therapeutics, Inc. (0J2O.L) Seasonal returns chart

https://uk.finance.yahoo.com/quote/0J2O.L/seasonality/
The article states that seasonality data is currently unavailable for Halozyme Therapeutics, Inc. (0J2O.L). It provides the current stock price and change for 0J2O.L and notes an upcoming Q3 2026 earnings call.

What Did Halozyme Stock Investors Miss Before The Run?

https://www.trefis.com/stock/halo/articles/620961/what-did-halozyme-stock-investors-miss-before-the-run/2026-10-28
Halozyme Therapeutics (HALO) stock significantly outperformed the S&P 500 and peers over the last year, largely driven by record royalty revenue from its ENHANZE technology. This growth was openly discussed by management and reflected in raised forecasts well before the stock's major run, suggesting investors could have identified the trend earlier. The company continues to see royalty growth, albeit at a slower pace, and expects further increases through the second half of the year.

Halozyme Therapeutics (HALO) Could Be 16% Below Fair Value After Royalty Fueled Growth

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/halozyme-therapeutics-halo-could-be-16-below-fair-value-afte
Halozyme Therapeutics (HALO) has seen significant share price growth due to strong royalty streams and new subcutaneous therapies, leading to an 82.07% year-to-date return. Despite this, Simply Wall St's analysis suggests the stock is currently 16% undervalued, with a narrative fair value of $151.83 compared to its last close of $128.01. However, its P/E ratio of 35.1x is higher than the US Biotechs average, indicating potential valuation risk if market sentiment shifts.

Halozyme Therapeutics (HALO) Could Be 16% Below Fair Value After Royalty Fueled Growth

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/halozyme-therapeutics-halo-could-be-16-below-fair-value-afte/amp
Halozyme Therapeutics (HALO) has seen its share price climb significantly due to strong royalty streams and the scaling of new subcutaneous therapies, leading to robust operating performance. Despite this growth, the stock is considered 16% undervalued by many investors, who peg its fair value at $151.83. The company is evolving beyond its single ENHANZE® platform to a broader portfolio of drug-delivery technologies, though it faces execution risks with newer platforms and mixed sentiment regarding its valuation.

Halozyme Therapeutics stock hits all-time high at 125.53 USD

https://www.investing.com/news/company-news/halozyme-therapeutics-stock-hits-alltime-high-at-12553-usd-93CH-4970036
Halozyme Therapeutics Inc. (HALO) stock reached an all-time high of $125.53, reflecting an 89.33% increase over the past 12 months. This growth follows significant company developments, including a $1.5 billion convertible notes offering and a favorable patent ruling against Merck & Co. H.C. Wainwright reiterated a Buy rating on the stock, citing the company's strong performance and recent FDA approval of a cancer treatment utilizing Halozyme's ENHANZE technology.
Advertisement

Halozyme Therapeutics, Inc. Estimates – NASDAQ:HALO

https://www.tradingview.com/symbols/NASDAQ-HALO/financials-estimates/?category=balance_sheet
This article provides an overview of Halozyme Therapeutics, Inc. (NASDAQ: HALO) financials, including actuals and analyst estimates for income statements, balance sheets, cash flow, and valuation metrics. It highlights that users can compare reported financial data with average, high, and low estimates and visualize trends over time. The platform also offers disclaimers about investment advice and encourages users to conduct their own research.

Will EPS Estimate Upgrade Change Halozyme Stock Narrative

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/will-eps-estimate-upgrade-change-halozyme-stock-narrative/amp
Halozyme Therapeutics has seen a significant upgrade in analyst EPS estimates for the current year, alongside a strong 82% year-to-date return, reflecting increased investor focus on its earnings potential. The company's investment narrative centers on its licensing model for subcutaneous drug delivery and the growth of its ENHANZE-based products, with future catalysts including new platform execution and partner label expansions. Despite a potential 13% downside to its current price based on fair value estimates, the core narrative remains strong due to increasing adoption trends.

Halozyme to Report Third Quarter 2026 Financial and Operating Results

https://www.moomoo.com/news/post/1002025389/halozyme-to-report-third-quarter-2026-financial-and-operating-results
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is scheduled to release its third-quarter 2026 financial and operating results after the market closes on Tuesday, November 5, 2026. The company will host a conference call and webcast to discuss these results on the same day at 4:30 p.m. ET.

Halozyme Therapeutics Stock: 6 Straight Green Days, Up 14%

https://www.trefis.com/stock/halo/articles/619900/halozyme-therapeutics-stock-6-straight-green-days-up-14/2026-10-22
Halozyme Therapeutics (HALO) stock has seen a significant surge, rising for six consecutive trading days and gaining 13.9%, adding approximately $1.8 billion to its market value. This impressive performance, largely independent of the broader S&P 500, is supported by strong fundamentals, including 41.2% revenue growth over the last twelve months and a 55.9% operating margin. The article emphasizes that while such streaks are notable, investors should maintain discipline and consider diversified strategies like the Trefis High Quality (HQ) Portfolio.

H.C. Wainwright reaffirms USD 130 target for Halozyme Therapeutics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/h-c-wainwright-reaffirms-usd-130-target-for-halozyme-therapeutics-stock/70376066
H.C. Wainwright has reaffirmed a Buy rating and a $130.00 price target for Halozyme Therapeutics (HALO), indicating a potential upside from its current trading levels. The company reported strong second-quarter revenue of $481.00 million, a 47.70 percent increase year-over-year, and expects its next earnings report on November 2, 2026. Halozyme's stock is trading near its 52-week high, supported by its ENHANZE platform and drug-delivery partnerships.
Advertisement

Zacks.com featured highlights include Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and Chevron

https://finance.yahoo.com/markets/stocks/articles/zacks-com-featured-highlights-halozyme-120000048.html
This article from Zacks.com highlights five stocks—Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources, and Chevron—identified using a relative price strength strategy. The strategy focuses on companies outperforming the S&P 500 over 1-3 months with strong fundamentals and positive analyst estimate revisions. The selected stocks are presented with details on their expected earnings growth, VGM Scores, and recent stock performance, suggesting they are good buys in a volatile market.

Zacks.com featured highlights include Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and Chevron

https://ca.finance.yahoo.com/news/zacks-com-featured-highlights-halozyme-120000048.html
This article highlights five stocks—Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions Holdings, Permian Resources, and Chevron Corp.—identified using a relative price strength strategy, which focuses on companies outperforming the S&P 500 and their peers. Despite market volatility, these companies exhibit strong fundamentals, positive earnings growth estimates, and significant stock gains over the past year. The strategy emphasizes consistent outperformance and analyst optimism for future earnings.

Is Halozyme Therapeutics (HALO) Undervalued On Its Expanded Argenx Licensing Deal?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/is-halozyme-therapeutics-halo-undervalued-on-its-expanded-ar
Halozyme Therapeutics (HALO) has expanded its licensing deal with argenx, leading to strong recent share price performance. While a narrative suggests it is 19.8% undervalued with a fair value of $151.83, its current P/E ratio of 33.4x is almost double the US Biotech average, indicating it's richly priced based on current earnings. Investors are left to weigh the potential of future platform growth against its high current valuation.

Missed Halozyme Therapeutics' 82% Run? What Holders Saw

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/missed-halozyme-therapeutics-82-run-what-holders-saw
Halozyme Therapeutics shareholders saw an 81.8% return over the past year, driven by the strong performance of its ENHANZE platform. This article revisits the bullish and bearish arguments investors were weighing a year ago, noting that while revenue and earnings supported the bullish view, net margin expansion remained unproven. The current stock price of US$122 suggests strong royalty income and high profitability are already factored in, with future growth dependent on continued partner acquisition for ENHANZE and Hypercon.

Halozyme Therapeutics stock closed at USD 121.84, 0.49 percent below its 52-week high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/halozyme-therapeutics-stock-closed-at-usd-121-84-0-49-percent-below-its-52-week-high/70350959
Halozyme Therapeutics stock closed at $121.84, just 0.49% below its 52-week high, with a year-to-date gain of 81.04% as of October 16, 2026. The company is set to report its Q3 2026 results on November 2, 2026, with an estimated consensus revenue of $490.85 million. In Q2 2026, Halozyme reported $481.00 million in revenue and $229.91 million in net income, marking a 47.70% year-over-year revenue increase.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement